Substance / Medication

Blinatumomab

Overview

Active Ingredient
blinatumomab
RxNorm CUI
1597258

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
da Silva Anderson Matheus Pereira, Filho Luciano Falcão Carneiro, Han Mariana Lee et al. · Clin Lymphoma Myeloma Leuk · 2025
PMID: 40436683Meta-Analysis
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis.
Liu Heng, Xi Rui, Mao Dongfeng et al. · Clin Lymphoma Myeloma Leuk · 2023
PMID: 36593170Meta-Analysis
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
Marrapodi Maria Maddalena, Mascolo Annamaria, di Mauro Gabriella et al. · Front Pediatr · 2022
PMID: 35935358Meta-AnalysisFull text (PMC)
A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Zachery, Coalter Carli, Gresham Vanessa et al. · Ann Pharmacother · 2021
PMID: 33435716Meta-Analysis
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Gupta Sumit, Rau Rachel E, Kairalla John A et al. · N Engl J Med · 2025
PMID: 39651791RCTFull text (PMC)
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Litzow Mark R, Sun Zhuoxin, Mattison Ryan J et al. · N Engl J Med · 2024
PMID: 39047240RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Blinatumomab (substance)
SNOMED CT
716122004
UMLS CUI
C3853839
RxNorm CUI
1597258

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.